Fisher Clinical Services, Inc. Application to Import Controlled Substances
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
Fisher Clinical Services, Inc. has formally applied to the U.S. Drug Enforcement Administration (DEA) to be registered as an importer of one or more basic classes of controlled substances. This notice, published on April 1, 2026, fulfills the DEA's regulatory obligation to publicly announce such applications and invite comment or objection from interested parties. The registration, if approved, would authorize Fisher Clinical Services — a clinical supply chain and logistics company — to import controlled substances, likely for use in clinical trials or pharmaceutical research and distribution. The specific drug classes and schedules involved are referenced in supplementary information accompanying the official Federal Register notice. Under the Controlled Substances Act, any entity wishing to import Schedule I–V substances must obtain DEA registration. This application initiates that review process, during which the DEA evaluates the applicant's qualifications, security measures, and intended use before granting or denying the registration.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Fisher Clinical Services, Inc. has applied for DEA importer registration as of April 1, 2026
- Application covers one or more basic classes of controlled substances (specific schedules in supplementary notice)
- If approved, Fisher gains legal authority to import Schedule I–V controlled substances into the United States
+ 3 more changes with Pro
Obligations
What this law requires
Fisher Clinical Services, Inc. must obtain DEA registration as an importer of controlled substances before importing any Schedule I-V substances
Fisher Clinical Services, Inc. must demonstrate qualifications satisfactory to the DEA as part of the registration application review process
Fisher Clinical Services, Inc. must implement and maintain security measures as evaluated and required by the DEA during the registration review
Fisher Clinical Services, Inc. must specify and document the intended use of imported controlled substances (e.g., clinical trials, pharmaceutical research and distribution) in the application
The DEA must publish notice of the application and invite public comment or objection from interested parties